DDW sits down with Mark Matson, Senior Solution Specialist for Sensor Cloud at Medidata, a Dassault Systèmes company, about the use of digital biomarkers in life sciences and how they can help advance our understanding of disease. How do we define digital biomarkers? Digital biomarkers are data, or… Read More
Listen to this article on the DDW Podcast: Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J Mark Treherne, Dr Jenny Barnett and Dr Paula Moran. … Read More
News round-up for 3-7 October by DDW Digital Content Editor Diana Spencer This week has brought new trial results and regulatory approvals shedding light and bringing hope into therapy areas of unmet need. The University of Birmingham and… Read More
The University of Birmingham has published the results of a study undertaken in head and neck squamous cell carcinoma (HNSCC) by liquid biopsy company ANGLE, which characterised the epithelial-mesenchymal transition (EMT) status of circulating tumour cells (CTCs). EMT is clinically significant due to its role in tumour… Read More
The National Institute of Health and Care Excellence (NICE) has confirmed its decision not to recommend olaparib for previously treated metastatic prostate cancer in patients with BRCA gene mutations. The Institute of Cancer Research (ICR) has called the decision ‘disappointing’ and ‘frustrating’. It means that men in England and Wales… Read More
The amount of SARS-CoV-2 antibodies in the blood of patients hospitalised with Covid-19 could be used to predict illness severity and other clinical outcomes. A new study, published in the Annals of Internal Medicine, shows that higher levels of viral antigen in the blood, which… Read More
Molecular genetics company Mainz Biomed has enrolled its first patient in an international clinical study assessing the potential combination of gene expression (mRNA) biomarkers with a diagnostic test for colorectal cancer. The ColoFuture clinical study will see Mainz Biomed integrate a portfolio of novel gene expression (mRNA)… Read More
Suchita Gupta examines the immunochemistry reagents market post Covid-19. Immunohistochemistry (IHC) is referred to as the study of a branch of chemistry including the study of various components and functions of the immune system with the application of antigen & antibodies as chemical reagents. Read More
PreOmics has raised €13.5 million in a Series B financing round provided by Bruker Corporation, which is expected to broaden the market opportunities for both PreOmics’ platform technologies and Bruker’s proteomics platform with more complete, automated workflow solutions for academic and clinical researchers, for biomarker discovery and diagnostics companies, as well as for… Read More
This On Demand webinar by Olink features Bill Hunt, Director of Product Management at Fluidigm, and Dr Jenny Rubin, Development Engineer at Olink Proteomics. The webinar examines the new Olink Signature Q100, a benchtop system for protein biomarker analysis. Hunt discusses “Signature Q100 System – Evolution of workhorse for protein expression”, while Rubin… Read More
Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia. Currently, there are no treatments on the market for cognitive impairment associated with schizophrenia, despite efforts by pharmaceutical companies over… Read More
Illumina and Merck have partnered to develop and commercialise tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumours are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina’s TruSight Oncology 500 (TSO… Read More
Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven. … Read More
In the UK, a University of Manchester-led team of scientists has discovered that the most common form of adult blindness is probably caused by a failure of at least one of five proteins to regulate the immune system. The breakthrough could one day herald the development of transformative treatments for… Read More
Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel… Read More
Multiplex assays allow researchers to measure multiple biomarkers simultaneously, offering the advantage of harvesting more insightful data to inform better decision-making, accelerate research, and increase the probability of discovery. Enabling biomarker discovery and screening with FirePlex Multiplexed Assays features the expertise of Dr Paul Wylie. In this webinar with… Read More
